A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma - Trial NCT06084936
Access comprehensive clinical trial information for NCT06084936 through Pure Global AI's free database. This Phase 3 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 182 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hoffmann-La Roche
Timeline & Enrollment
Phase 3
Oct 22, 2023
Dec 31, 2026
Primary Outcome
Progression-free survival (PFS)
Summary
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with
 an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with
 rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06084936
Non-Device Trial